FDMT (4D Molecular Therapeutics) Interest Expense (Positive)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FDMT 4D Molecular Therapeutics Inc FDMT
55 GF Score
Price $11.70
GF Value $216.44
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is 4D Molecular Therapeutics Interest Expense (Positive)?

Interest Expense (Positive) only applies to insurance companies.

FDMT
55GF Score
4D Molecular Therapeutics Inc FDMT
Interest Expense (Positive) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is 4D Molecular Therapeutics (FDMT) Overvalued in 2026?

Based on GuruFocus' analysis, 4D Molecular Therapeutics stock appears to be undervalued. The current stock price of $11.70 is trading 94.6% below its estimated GF Value™ of $216.44. GuruFocus considers 4D Molecular Therapeutics to be Possible Value Trap.

Key valuation signals for FDMT:

  • Interest Expense (Positive):
  • GF Value™: $216.44 vs. price of $11.70 (94.6% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the FDMT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

4D Molecular Therapeutics Business Description

Address 5858 Horton Street, Suite 455, Emeryville, CA, USA, 94608
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).
55GF Score

Get the complete analysis for FDMT

Interest Expense (Positive) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.70
Price
$216.44
GF Value